AAV vector manufacturing process design and scalability - Bending the trajectory to address vector-associated immunotoxicities
- PMID: 35594866
- PMCID: PMC9171258
- DOI: 10.1016/j.ymthe.2022.05.004
AAV vector manufacturing process design and scalability - Bending the trajectory to address vector-associated immunotoxicities
References
- 
    - Rumachik N.G., Malaker S.A., Poweleit N., Maynard L.H., Adams C.M., Leib R.D., Cirolia G., Thomas D., Stamnes S., Holt K., et al. Methods matter: standard production platforms for recombinant AAV produce chemically and functionally distinct vectors. Mol. Ther. Meth. Clin. Dev. 2020;18:98–118. doi: 10.1016/j.omtm.2020.05.018. - DOI - PMC - PubMed
 
- 
    - Sihn C.-R., Handyside B., Liu S., Zhang L., Murphy R., Yates B., Xie L., Torres R., Russell C.B., O’Neill C.A., et al. Molecular analysis of AAV5-hFVIII-SQ vector-genome-processing kinetics in transduced mouse and nonhuman primate livers. Mol. Ther. Meth. Clin. Dev. 2022;24:142–153. doi: 10.1016/j.omtm.2021.12.004. - DOI - PMC - PubMed
 
MeSH terms
LinkOut - more resources
- Full Text Sources
- Other Literature Sources
 
        